Upstream Bio (UPB)
Developing verekitug, a TSLP-receptor antibody for severe respiratory diseases.
$5.05
vs last close−0.45 (−8.11%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 92.52% | 50.68M shares | |
|---|---|---|---|
| 153 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.31% | 167.4K shares | |
| 5 holders · as of Sep 17, 2026 | |||
| Other | ≈ 7.17% | 3.93M shares | |
| remainder | |||
54.77M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
13F, as of Jun 30, 2026
153 holders · 50.68M shares · 38 new positions · 103 increased · 30 reduced · 27 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 8.16M | 14.90% | +61.3K | Aug 13, 2026 |
| Orbimed Advisors LLC | 5.69M | 10.40% | 0 | Aug 14, 2026 |
| Norges Bank | 3.77M | 6.88% | +3.77Mnew | Aug 12, 2026 |
| BlackRock, Inc. | 3.75M | 6.85% | +382.7K | Aug 7, 2026 |
| Decheng Capital LLC | 2.72M | 4.98% | 0 | Aug 14, 2026 |
| Enavate Sciences GP, LLC | 2.46M | 4.49% | 0 | Aug 14, 2026 |
| Vanguard Capital Management LLC | 1.88M | 3.43% | +3.2K | Aug 13, 2026 |
| Millennium Management LLC | 1.14M | 2.09% | +206.5K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 14.80% | 7.94M | 13G | Aug 6, 2025 |
| AI Upstream LLCincl. Access Industries Holdings LLC, Access Industries Management, LLC +2 more | 10.70% | 5.49M | 13D | Oct 22, 2024 |
| OrbiMed Advisors LLCincl. OrbiMed Advisors Israel II Limited, OrbiMed Israel GP II, L.P. +1 more | 8.90% | 4.55M | 13D | Oct 17, 2024 |
| Norges Bank | 5.30% | 2.88M | 13G | Oct 24, 2025 |
| BlackRock, Inc. | 5.20% | 2.81M | 13G | Jul 30, 2026 |
| Decheng Capital Global Life Sciences Fund IV, L.P. | 5.00% | 2.72M | 13G | May 15, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 16, 2026 | Adam Houghtonofficer: Chief Business Officer | Sale | 700 | $5.49 | 22,901 |
| Sep 16, 2026 | Everett Rand Sutherlanddirector, officer: Chief Executive Officer | Sale | 2,095 | $5.49 | 68,717 |
| Sep 16, 2026 | Aaron Deykinofficer: Chief Medical Officer | Sale | 895 | $5.49 | 32,302 |
| Sep 16, 2026 | Allison Ambroseofficer: General Counsel | Sale | 485 | $5.49 | 15,563 |
| Sep 16, 2026 | Michael Grayofficer: CFO and COO | Sale | 853 | $5.49 | 27,942 |
House and Senate disclosures
Not reported.